We rate BioNTech SE a hold due to volatile performance, weak growth, and premium valuation amidst COVID-19 vaccine reliance.

The rest is history – Pfizer stepped in and licensed the technology, choosing the most promising of four potential mRNA vaccines from BioNTech. Both Moderna and Pfizer’s shots aced the quickly ...

The next stage for the technology will be the same step that both Moderna and BioNTech took during the pandemic – receiving an approval for an mRNA vaccine outside of COVID-19. If either company ...

In this review of RNA therapies, we paint an overview of what’s going on in a field that is addressing a number of diseases.

Moderna stock surged Wednesday after Oracle Chairman Larry Ellison praised the potential of AI in developing medicines.

In the fight against COVID-19, two FDA-approved mRNA vaccines were developed by Pfizer/BioNTech (BNT162b2) and Moderna (mRNA-1273), which produce ... and now an independent research fellow at the ...

BNT-314 is under clinical development by BioNTech and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 37% phase transition success rate (PTSR) ...

DB-1311 is under clinical development by BioNTech and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 37% phase transition success rate (PTSR) ...